Comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 vs 3mc Syndrome 3 C0796032
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Exogenous Maternal Derived Androgen and 3mc Syndrome 3 for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
A condition caused when a pregnant person takes hormone medications containing androgens, affecting fetal development. The fetus has XX chromosomes. Stopping the offending agent is key, with specialist care for affected infants.
3mc Syndrome 3 C0796032
Another rare variant of 3MC syndromes, a genetic disorder causing developmental differences and facial features. Care involves various specialists addressing individual needs.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Variable
3mc Syndrome 3 C0796032
0-0
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
severe
3mc Syndrome 3 C0796032
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Chronic
3mc Syndrome 3 C0796032
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
No
3mc Syndrome 3 C0796032
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
reproductive
3mc Syndrome 3 C0796032
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
endocrine
3mc Syndrome 3 C0796032
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-exogenous-maternal-derived-androgen-C5679874 and 3mc-syndrome-3-C0796032 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3mc Syndrome 3 C0796032 | Discriminating power |
|---|---|---|---|
| Genital appearance | May show androgen-related atypical genital development in a 46,XX fetus. | Genital differences are not the defining feature in the supplied description. | Moderate |
| Facial and developmental features | Not described as a multisystem craniofacial syndrome. | Described as developmental differences with characteristic facial features. | High |
| Exposure history | Linked to androgen-containing medication taken during pregnancy. | Described as a genetic variant without an exogenous exposure cause. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 when
Documented pregnancy exposure to androgen-containing medication
The supplied cause is exogenous maternal-derived androgen affecting an XX fetus.
High
Atypical genital development without a known genetic syndrome
Reproductive-system findings fit the described endocrine exposure mechanism.
Moderate
Need to stop an implicated medication
Stopping the offending agent is stated as key, with specialist infant care.
High
Choose 3mc Syndrome 3 C0796032 when
Congenital developmental differences and facial features
These are the features given for 3MC syndrome 3.
Moderate
Suspected inherited multisystem condition
The description classifies it as a rare genetic disorder.
Moderate
No relevant androgen exposure history
Absence of the stated exposure makes the left condition less likely, but does not confirm 3MC.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3mc Syndrome 3 C0796032 | Interpretation |
|---|---|---|---|
| Chromosomal or genetic evaluation | 46,XX is specified; no further genetic result is established here. | A genetic basis is described, but the exact test result is not supplied. | Testing supports classification; a clinician must interpret results. |
| Medication and pregnancy history | History of androgen-containing hormone medication is central. | No exogenous medication cause is described. | History can discriminate exposure-related DSD from a genetic syndrome. |
| Specialist clinical assessment | Focus on genital development and endocrine context. | Focus on developmental, facial, and individual congenital needs. | Assessment scope differs; neither finding alone establishes the diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
- Outcome
- Outcome is not established; stopping exposure and specialist care are emphasized.
- Factors
- Timing and nature of exposure, findings at birth, and access to specialist care.
3mc Syndrome 3 C0796032
- Outcome
- Described as moderate and chronic, but individual outcome is not established.
- Factors
- Specific developmental and congenital features and specialist support.
Time frame: From prenatal or congenital onset into ongoing childhood care; exact course unknown.
Etiology, severity, associated findings, and individualized care determine follow-up needs.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impact | Fetal sex development may be affected; broader outcomes are not established. Developmental differences are described, with variable individual needs. Severity labels differ, but exact outcomes are not supplied. |
| Need for specialist care | Specialist care is advised for affected infants. Care may involve multiple specialists according to needs. Both require individualized specialist planning. |
| Ongoing course | Listed as chronic despite removal of exposure being key. Listed as a chronic congenital condition. Long-term burden cannot be quantified from the source. |
Patient education highlights
- HighCause
The left condition is linked to pregnancy androgen exposure; 3MC syndrome 3 is described as genetic.
- HighMedication safety
Do not start or stop hormone medicines without clinician advice, especially during pregnancy.
- MediumFollow-up
Both conditions may need specialist review tailored to the child’s findings.